02nd week of 2021 patent applcation highlights part 10 |
Patent application number | Title | Published |
20210008168 | Conjugates - The present invention relates to a conjugate comprising a moiety of formula (I) or to conjugates of formula (I′) and to pharmaceutical compositions comprising such conjugates. | 2021-01-14 |
20210008169 | METHODS FOR TREATING AND DIAGNOSING METASTATIC LIVER CANCER - The present invention is directed to a method for treating or preventing cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an adropin stimulating agent. Further provided are a method and a kit for diagnosing or prognosing liver metastases in a subject. | 2021-01-14 |
20210008170 | TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETES - Certain embodiments are directed to methods for treating, ameliorating, or preventing exercise-induced or exercise-associated hypoglycemia comprising administration to a subject in need thereof a formulation(s) of glucagon or glucagon analog in an amount effective to treat, ameliorate, or prevent the condition. The subject can be administered a glucagon or a glucagon analog composition 1, 5, 10, 15 to 20, 25, 30 minutes prior to initiation of exercise. | 2021-01-14 |
20210008171 | MULTIPARTICULATE GRANULATE COMPRISING INSULIN - The present invention is directed to multiparticulate granulate compositions comprising particles of insulin and particles of an infant nutritional excipient, wherein the multiparticulate granulate is substantially free of layers of insulin and excipient, methods of making thereof, and methods of use thereof. | 2021-01-14 |
20210008172 | LONG-ACTING IGF-1 OR IGF-1 VARIANTS AND METHODS OF PRODUCING SAME - Compositions which include polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotropin attached to the carboxy terminus or amino terminus of an insulin-like growth factor 1 (IGF-1) or IGF-1 variant. Polynucleotides encoding the same are disclosed. Pharmaceutical compositions and pharmaceutical formulations comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed. | 2021-01-14 |
20210008173 | ENDOSTATIN PEPTIDES FOR THE TREATMENT OF TUMORS, FIBROSIS AND ACUTE LUNG INJURY - The present invention provides compositions and methods for treatment or prevention of tumor growth, fibrosis, acute lung injury or a combination thereof. In one embodiment, the composition comprises a peptide derived from the C-terminal region of endostatin. | 2021-01-14 |
20210008174 | Veterinary Composition Comprising Superoxide Dismutase and at Least One Hydrolysate of Proteins Rich in Bioassimilable Peptides - A veterinary composition comprising, in effective amounts, superoxide dismutase and at least one protein hydrolysate rich in bioassimilable peptides. | 2021-01-14 |
20210008175 | BACTERIOPHAGE LYSIN AND ANTIBIOTIC COMBINATIONS AGAINST GRAM POSITIVE BACTERIA - The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly Staphylococcal bacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s). | 2021-01-14 |
20210008176 | COMPOSITIONS COMPRISING SULFORAPHANE OR A SULFORAPHANE PRECURSOR AND MAGNESIUM - The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and magnesium or a salt or complex thereof. The invention also relates to the combination of a sulforaphane or a derivative thereof and magnesium or a salt or complex thereof. The invention also relates to the combination of a broccoli extract or powder and magnesium or a salt or complex thereof. The invention provides compositions and methods relating to these combinations. | 2021-01-14 |
20210008178 | FACTOR IX POLYPEPTIDES AND METHODS OF USE THEREOF - The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells. | 2021-01-14 |
20210008179 | MODIFIED FACTOR IX, AND COMPOSITIONS, METHODS AND USES FOR GENE TRANSFER TO CELLS, ORGANS, AND TISSUES - The invention relates to modified Factor IX coding sequence, expression cassette, vectors such as viral (e.g., lenti- or adeno-associated viral) vectors, and gene transfer methods and uses. In particular, to target Factor IX nucleic acid to cells, tissues or organs for expression (transcription) of Factor IX. | 2021-01-14 |
20210008180 | FORMULATIONS CONTAINING MUCIN-AFFECTING PROTEASES - Disclosed herein is a microsphere for delivery to a target area in a patients body. The microsphere contains a mucin-affecting protease loaded therein and is adapted to release the mucin-affecting protease in a sustained manner when exposed to physiological conditions. Also disclosed are pharmaceutical compositions comprising the microspheres and methods of treatment involving the microspheres. | 2021-01-14 |
20210008181 | Treatment Of Ophthalmic Conditions With Angiopoietin-Like 7 (ANGPTL7) Inhibitors - The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human angiopoietin like 7 (ANGPTL7) variant nucleic acid molecules and variant polypeptides, and ANGPTL7 variant nucleic acid molecules and variant polypeptides. | 2021-01-14 |
20210008182 | METHODS FOR REDUCING RISK OF ONSET OF ACUTE GRAFT VERSUS HOST DISEASE AFTER HEMATOPOEITIC CELL TRANSPLANTATION - This disclosure relates to methods for preventing or reducing the risk of development of graft versus host disease (GVHD) in patients receiving hematopoietic cell transplantation (HCT) by particular methods of administering alpha-1 antitrypsin (A1AT or AAT) to patients both prior to and following and HCT procedure. The disclosure also relates to specific methods of treating acute GVHD (aGVHD) after HCT with A1AT. | 2021-01-14 |
20210008183 | METHODS OF INDUCING IMMUNE TOLERANCE AND REDUCING ANTI-DRUG ANTIBODY RESPONSE - The present invention disclosed methods for suppressing or preventing an immune response to a specific antigen in a subject, comprising administering to the subject, the specific antigen by an intravenous route followed by an inhalation route. | 2021-01-14 |
20210008184 | COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSES TO EIMERIA OR LIMITING EIMERIA INFECTION - Vaccine, vectors and methods of using the vaccine vectors to enhance the immune response to an Apicomplexan parasite and reduce the morbidity or mortality associated with subsequent infection are provided herein. The vaccine vectors include a polynucleotide encoding a Rhomboid polypeptide and optionally include an immune-stimulatory polypeptide suitably expressed on the surface of the vaccine vector. | 2021-01-14 |
20210008185 | Treatment and Prophylaxis of Amyloidosis - Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease. | 2021-01-14 |
20210008186 | IMMUNOTHERAPY OF LEISHMANIASIS - The present invention relates to methods and compositions for treating leishmaniasis in mammals. The invention more particularly relates to immunotherapeutic treatment of | 2021-01-14 |
20210008187 | Autologous Cancer Vaccines - The invention relates to an autologous cancer vaccine and also to the method for producing same comprising the following steps: a) extracting the proteins contained in a serum or plasma sample obtained from a patient suffering from cancer; and b) bringing the proteins extracted in step a) into contact with particles of hydroxyapatite and/or tricalcium phosphate. | 2021-01-14 |
20210008188 | COMPOSITIONS AND METHODS FOR T CELL DELIVERY OF THERAPEUTIC MOLECULES - The present invention includes compositions and methods for modifying a T cell with a nucleic acid encoding a switch molecule comprising an extracellular domain comprising a membrane receptor or fragment thereof and an intracellular domain comprising a signaling receptor or fragment thereof. In one aspect, a method comprises introducing a nucleic acid encoding a switch molecule and a nucleic acid encoding a soluble fusion protein and/or a nucleic acid encoding a bispecific antibody into a population of cells comprising T cells, wherein the T cells transiently expresses the switch molecule and soluble fusion protein or bispecific antibody. In other aspect, compositions of T cells and methods of treating a disease or condition, such as cancer or an autoimmune disease, are also included. | 2021-01-14 |
20210008189 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, SUCH AS ACUTE MYELOID LEUKEMIA (AML) - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 2021-01-14 |
20210008190 | Methods and agents including STING agonist to treat tumor - This disclosure provides cell surface anchoring conjugates, formulations comprising cell surface anchoring conjugates, STING agonist and methods of using the same for boosting immunity in a subject and treating tumor cell and cancer. | 2021-01-14 |
20210008191 | A METHOD FOR LYOPHILIZING LIVE VACCINE STRAINS OF FRANCISELLA TULARENSIS - There are provided compositions and methods for lyophilization and/or storage of live vaccine strains of | 2021-01-14 |
20210008192 | MULTIPLE ANTIGEN PRESENTING SYSTEM (MAPS)-BASED STAPHYLOCOCCUS AUREUS VACCINE, IMMUNOGENIC COMPOSITION, AND USES THEREOF - The present embodiments provide for an | 2021-01-14 |
20210008193 | PROTEIN ANTIGENS FOR VACCINATING AGAINST NONTYPEABLE HAEMOPHILUS INFLUENZAE - The present invention includes methods for treating and/or immunizing against | 2021-01-14 |
20210008194 | MDCK SUSPENSION CELL LINES IN SERUM-FREE, CHEMICALLY-DEFINED MEDIA FOR VACCINE PRODUCTION - Disclosed is an adapted Madin-Darby canine kidney cell line capable of suspension culture in the absence of serum, and a chemically-defined medium for culture of the adapted MDCK cell line. Further disclosed are culture methods for growing the adapted MDCK cell line and methods for producing a vaccine from the adapted MDCK cell line grown in the chemically-defined medium. | 2021-01-14 |
20210008195 | VACCINES AGAINST HENDRA AND NIPAH VIRUS INFECTION - Disclosed is a method of protecting an animal in need thereof from Hendra or Nipah virus infection comprising administering to said animal a single dose of a vaccine, the vaccine comprising:an antigen component comprising a Hendra antigen or a Nipah antigen; and an adjuvant comprising oil, polycationic carrier and a CpG containing immunostimulatory oligonucleotide, wherein the vaccine is a W/O emulsion. | 2021-01-14 |
20210008196 | DUCK HEPATITIS A VIRUS TYPE 3 MUTANT CH-P60-117C AND CONSTRUCTION THEREOF - Disclosed herein are a duck hepatitis A virus type 3 (DHAV-3) mutant CH-P60-117C and a construction method thereof. The DHAV-3 mutant CH-P60-117C is constructed by mutating A at position 117 of 5′-UTR of the genome of the DHAV-3 virulent strain to C; mutating T at position 1142 to A to mutate tyrosine-164 of VP0 protein of the parent strain to asparagine; and mutating C at position 4334 to A so that leucine-71 of the viral protein 2C of the parent strain is mutated to isoleucine. | 2021-01-14 |
20210008197 | PYRIMIDINE COMPOUND - The present invention provides a compound of the formula (1): | 2021-01-14 |
20210008198 | IMMUNOTHERAPEUTIC CONSTRUCTS AND METHODS OF THEIR USE - Disclosed herein are immunotherapeutic constructs comprising a delivery particle, at least one adjuvant, and one or more therapeutic agents/compounds that cause antigen release and/or modulate immunosuppressive tumor microenvironment. These immunotherapeutic constructs create adaptive immunity or anti-cancer immune response(s) that can be used, for instance, to prevent and treat broad types of cancer. Further disclosed are uses of the immunotherapeutic constructs, including to prevent and treat cancer in humans and animals. | 2021-01-14 |
20210008199 | METHODS AND COMPOSITIONS COMPRISING REDUCED LEVEL OF HOST CELL PROTEINS - The present disclosure pertains to compositions with reduced presence of host-cell proteins and methods of making such compositions. In particular, it pertains to compositions methods of making compositions with reduced presence of host-cell proteins from a host-cell. | 2021-01-14 |
20210008200 | HEMATOPOIETIC STEM CELLS IN COMBINATORIAL THERAPY WITH IMMUNE CHECKPOINT INHIBITORS AGAINST CANCER - The novel synergistic combination of immune checkpoint blockade and hematopoietic stem cell transplantation and/or hematopoietic stem cell mobilization yield synergistic effects in disease therapy. | 2021-01-14 |
20210008201 | ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3) - This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction; and allow ligand binding (e.g., neuregulin), whilst preventing ligand-induced activation of signal transduction. These antibodies or fragments can be used to treat a number of diseases or disorders characterized by increased levels of HER3 expression (e.g., esophageal cancer). These antibodies or fragments can be used to treat a number of diseases or disorders characterized by the antibodies or fragments ability to decrease tissue weight (e.g., prostate or uterine weights) or to induce atrophy of tissue (e.g., atrophy of male breast). | 2021-01-14 |
20210008202 | Using Paper with Heightened KELEA to Enhance the Alternative Cellular Energy (ACE) Pathway - Placing paper onto the skin of an individual is used to support the alternative cellular energy (ACE) pathway in a human or animal subject. The benefits can be increased if the paper is first provided with a heightened level of KELEA by being stored for several hours in the vicinity of containers of KELEA activated water. KELEA is an abbreviation of “kinetic energy limiting electrostatic attraction.” The ACE pathway is a form of cellular energy, which is different from that provided by the calories in food or, in the case of plants and certain bacteria, by photosynthesis. In relative terms, the direct contact of the body with paper that has a heightened level of KELEA achieves better transfer of KELEA to living life forms than does the indirect exposure of the body to KELEA activated water contained in wearable waterceutical pouches. The direction of transfer of KELEA between the skin of an individual and paper can also be used to monitor the activity of the ACE pathway in the individual. Paper with heightened KELEA has numerous therapeutic and increased wellbeing applications in humans, animals, and plants. | 2021-01-14 |
20210008203 | Long-Lived Gadolinium Based Tumor Targeted Imaging and Therapy Agents - Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula: | 2021-01-14 |
20210008204 | COMPOSITIONS AND METHODS OF DETECTING AND TREATING ALZHEIMER'S DISEASE - The invention provides microbubbles and/or nanodroplets labeled with diagnostic and/or therapeutic ligands that are useful in the detection and treatment of Alzheimer's disease, or related diseases and conditions, as well as methods of preparation and use thereof. | 2021-01-14 |
20210008205 | HYPERTHERMIC CANCEROUS TISSUE ABLATION - A system and method for hyperthermic ablation of cancerous tissue of a human patient is disclosed. A system and method include a vessel that is sized and adapted for receiving the human patient, and a circulation device outside of the vessel for circulating a thermally conductive liquid to and from the vessel, such that the portion of the human patient enclosed in the containment suit is at least partially submerged in the thermally conductive liquid when the human patient is in the vessel. The system and method further include a set of electromagnetic transmission coils at least partially around the vessel for inducing an alternating electromagnetic field around the human patient, the alternating electromagnetic field being directed, via the thermally conductive liquid, to the cancerous tissue that has been provided a conductive nanoparticle, to provide hyperthermic ablation of the cancerous tissue. | 2021-01-14 |
20210008206 | ADENOSINE PATHWAY INHIBITORS FOR CANCER TREATMENT - Provided herein are, inter alia, methods for treating cancer in subjects expressing elevated levels of adenosine A2A receptors, and optionally further expressing elevated levels of CD73 and/or PD-L1, by administering adenosine pathway inhibitors. | 2021-01-14 |
20210008207 | Agents and Methods for the Prevention or Treatment of H. Pylori Infections - The present invention relates to inhibitors of the interaction between | 2021-01-14 |
20210008208 | SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONJUGATION - The present invention provides Shiga toxin A Subunit derived polypeptides, scaffolds, and cell-targeting molecules comprising amino acid substitutions which equip the molecules with site-specific positions (and often unique amino acid residues in the molecule) for linking other molecules while retaining Shiga toxin function(s), such as, e.g., efficient intracellular routing and/or potent cytotoxicity. The present invention also provides cell-targeting molecules, and/or components thereof, which comprise site-specific positions for linking other molecules, such as, e.g., agents that alters a property of the cell-targeting molecule or a cargo for delivery. Certain molecules comprising a polypeptide of the present invention exhibit reduced immunogenicity and/or are well-tolerated by mammals. The cell-targeting molecules of the present invention, and compositions thereof, have uses, e.g., for the selective delivery of cargos to target-expressing cells and as diagnostic and/or therapeutic molecules for the treatment of a variety of diseases, disorders, and conditions, which include genetic disorders, genetic predispositions, infections, cancers, tumors, growth abnormalities, and/or immune disorders. | 2021-01-14 |
20210008209 | COMBINATION THERAPY FOR TTR AMYLOIDOSIS - The present invention is directed to compositions and methods for the treatment of transthyretin-associated (TTR) amyloidosis and in particular, compositions and methods that employ an effective amount of tolcapone and an RNAi molecule in combination for the treatment of transthyretin-associated amyloidosis. | 2021-01-14 |
20210008210 | METHODS FOR PROTECTING AND TREATING TRAUMATIC BRAIN INJURY, CONCUSSION AND BRAIN INFLAMMATION WITH INTRANASAL INSULIN - The present system is directed in several embodiments to a method of administration of a therapeutic composition for protection of the brain of a subject at risk of injury leading to traumatic brain injury (TBI) and/or treatment of injury to the brain resulting from TBI. The method includes administering one or more therapeutic compositions comprising an effective amount of insulin directly to the subject patient's CNS, with no to minimal systemic exposure. Preferably, this method comprises administration of an effective amount of insulin to the upper third of a patient's nasal cavity, thereby bypassing the patient's blood-brain barrier and delivering the therapeutic composition directly to the patient's central nervous system. | 2021-01-14 |
20210008211 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T | 2021-01-14 |
20210008212 | Solid Carriers for Improved Delivery of Active Ingredients in Pharmaceutical Compositions - The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritional agents, cosmeceuticals and diagnostic agents. | 2021-01-14 |
20210008213 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENCAPSULATED AGENTS - Self-assembled gel compositions including a gelator, e.g., an enzyme-cleavable gelator, e.g., having a molecular weight of 2500 or less, are described. The self-assembled gel compositions can encapsulate one or more agents. Methods of making the self-assembled gel compositions, and methods of drug delivery using the self-assembled gel compositions are also described. | 2021-01-14 |
20210008214 | TRANSDERMAL FORMULATIONS - The present disclosure is directed to transdermal and moisturizing compositions. | 2021-01-14 |
20210008215 | OPTIMIZING DRUG DELIVERY - This invention teaches a method of increasing the bioavailability, safety and efficacy of a cancer drug incorporated in a nanocarrier such as liposomes, micelles, dendrimeres, nanoemulsion, nanoparticles and antibody drug conjugates. It does so by administering pre-blocking blank liposomes to the patient several hours before the drug incorporated nanocarrier is administered. Blocking the reticuloendothelial system (RES) will prevent it from taking up the drug incorporated nanocarrier and hence improve the safety and efficacy of the drug. | 2021-01-14 |
20210008216 | BIODEGRADABLE DRUG DELIVERY FOR HYDROPHOBIC COMPOSITIONS - A biodegradable drug delivery compositions comprising a triblock copolymer containing a polyester and a polyethylene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as at least one pharmaceutically active principle or hydrophobic active principle such as medroxyprogesterone acetate, levonorgestrel, cyclosporine, progesterone or bupivacaine is disclosed. | 2021-01-14 |
20210008217 | Tumor Homing Statin Derivatives - The present invention generally relates to tumor homing statin derivatives (THSD) and their use for therapy, in particular cancer therapy. These THSD comprise three moieties: a statin moiety which comprises a dihydroxyheptanoic acid unit (DHHA) fixated by linkage into its open chain form, a heptamethine carbocyanine dye (HMCD) moiety, and a linker that conjugates the DHHA of the statin to the dye moiety. The linker is linked to the DHHA via an ester bond (ester-linked statin derivative or ELSD), or via an amide bond (amide-linked statin derivative or ALSD). Thus linked to the DHHA, the linker provides a relatively stable link either for essentially no hydrolysis/statin release after administration, or preferably for very slow hydrolysis and statin release, as is the case for the ELSD. Embodiments include methods to provide the desired THSD, in particular the ELSD, with the DHHA in its open chain form. The invention also relates to methods wherein one or more ELSD is administered to a patient in a therapeutically effective amount, and methods wherein an ELSD and an ALSD are co-administered in a coordinated administration schedule. Advantages of the THSD and their use include, among others, improved efficacy and dose-response, and decreased statin-associated side effects. | 2021-01-14 |
20210008218 | MULTI-ARM TARGETING ANTI-CANCER CONJUGATE - A multi-branched dnig conjugate of formula (I) or a pharmaceutically acceptable salt thereof. In the formula, R is an organic center, POLY is a polymer, L is a multivalent linker, T is a targeting molecule, D is an active agent, and q is any integer between 3 and 8. The symbol “*” in L represents a junction point of the multivalent linker L and the targeting molecule T, “#” represents a junction point of the multivalent linker L and the active agent D, and “%” represents a junction point of the multivalent linker L and POLY. 1 is any integer between 2 and 20, and m and n are each an integer between 0 and 10. T is iRGD, cRGD, tLyp-1, Lyp-1, RPARPAR, Angiopep2, or GE11. D is a camptothecin drug. | 2021-01-14 |
20210008219 | LONG-ACTING ADRENOMEDULLIN DERIVATIVE - The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. In an exemplary embodiment, the invention relates to a compound represented by formula (I): A-CH | 2021-01-14 |
20210008220 | PHARMACEUTICAL COMPOSITIONS CONTAINING POLYROTAXANES - Disclosed herein are a polyrotaxane conjugated metal chelators and selectively cleavable linkers. The compositions have prolonged plasma residence time, and upon contact with the appropriate chemical environment, are cleaved and then renally and fecally cleared. | 2021-01-14 |
20210008221 | METHODS, SYSTEMS, AND COMPOSITIONS FOR INHIBITING VIRULANCE OF A/E FAMILY PATHOGENS - The present invention features methods, systems, and compositions for inhibiting function of EspZ or an EspZ equivalent, and for inhibiting or reducing virulence of pathogens that utilize EspZ or EspZ equivalent, such as those pathogens that belong to the attaching-effacing (A/E) family. The methods may feature the use of an inhibitor peptide that targets at least a portion of EspZ, such as one of the transmembrane domains. In certain embodiments, the inhibitor peptide disrupts proper dimerization or oligomerization of EspZ. | 2021-01-14 |
20210008222 | PLANT VIRUS PARTICLES FOR DELIVERY OF ANTIMITOTIC AGENTS - Anti-lymphoma plant virus particles are described. The anti-lymphoma plant virus particles include a filamentous or rod-shaped plant virus particle linked to an antimitotic agent. A therapeutically effective amount of an anti-lymphoma plant virus particle can be administered to a subject to provide a method of treating lymphoma. | 2021-01-14 |
20210008223 | SYNTHETIC PLATELETS - Provided herein are particles comprising a polymer substrate comprising one or more hyaluronic acid chains; and two or more peptide moieties bound directly to each hyaluronic acid chain. In some embodiments, the two or more peptide moieties comprising collagen-binding peptide (CBP) and von Willebrand binding peptide (VBP). The particles can be utilized in, e.g., methods of hemostatic treatment. | 2021-01-14 |
20210008224 | COMPOSITION FOR GENE THERAPY OF THE CENTRAL NERVOUS SYSTEM, PROCESS OF PRODUCTION AND USE THEREOF - The present invention describes a composition for gene therapy of the central nervous system comprising non-viral carriers of nanometric size (<1.0 micrometer) complexed with at least one nucleic acid for purposes of gene therapy via nasal administration, having as main target the central nervous system and the processes for obtaining such carriers. The present invention belongs to the field of nanotechnology and consists of aqueous formulations that can be used in the pharmaceutical and medical fields. | 2021-01-14 |
20210008225 | COMPOSITIONS AND METHODS FOR TREATING SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY (SSADHD) - Provided herein are compositions and methods for treating succinic semialdehyde dehydrogenase deficiency (SSADHD). Compositions may include a gene encoding a functional succinic semialdehyde dehydrogenase (SSADH) enzyme, such as ALDH5A1, operably linked to a targeting vector. The functional SSADH enzyme is envisioned to lower the levels of circulating gamma-hydroxybutyric acid (GHB) and γ-aminobutyric acid (GABA). In some embodiments, combination therapies are envisioned, comprising administering to the subject therapeutically effective amounts of a combination of a composition comprising a gene encoding a functional SSADH enzyme operably linked to a targeting vector; one or more mTOR inhibitors; and a GABA-T inhibitor. Suitable mTOR inhibitors include rapamycin, while suitable GABA-T inhibitors include vigabatrin. | 2021-01-14 |
20210008226 | SYSTEMIC DELIVERY OF MYOSTATIN SHORT INTERFERING NUCLEIC ACIDS (SINA) CONJUGATED TO A LIPOPHILIC MOIETY - The present invention provides methods comprising the in vivo delivery of small nucleic acid molecules capable of mediating RNA interference and reducing the expression of myostatin, wherein the small nucleic acid molecules are introduced to a subject by systemic administration. Specifically, the invention relates to methods comprising the in vivo delivery of short interfering nucleic acid (siNA) molecules that target a myostatin gene expressed by a subject, wherein the siNA molecule is conjugated to a lipophilic moiety, such as cholesterol. The myostatin siNA conjugates that are delivered as per the methods disclosed are useful to modulate the in vivo expression of myostatin, increase muscle mass and/or enhance muscle performance. Use of the disclosed methods is further indicated for treating musculoskeletal diseases or disorders and/or diseases or disorders that result in conditions in which muscle is adversely affected. | 2021-01-14 |
20210008227 | GENE THERAPY FOR SPINAL CORD DISORDERS - This disclosure provides methods and compositions for treating disorders or injuries that affect motor function and control in a subject. In one aspect, the invention provides a method to deliver a transgene to a subject's spinal cord by administering a recombinant neurotropic viral vector containing the transgene. The viral vector delivers the transgene to a region of the deep cerebellar nuclei region of the brain. Also provided are compositions and methods to deliver a transgene to a subject's spinal cord by administering a recombinant neurotropic viral vector containing the transgene to the motor cortex region of the subject's brain. | 2021-01-14 |
20210008228 | Metal Oxide Nanoparticle-Based Magnetic Resonance Imaging Contrast Agent with a Central Cavity - The present invention relates to a magnetic resonance imaging (MRI) contrast agent, particularly an MRI contrast agent derived from nanoparticle that is porous first metal-doped second metal oxide nanoparticle with a central cavity, and a method for producing the same. The MEI contrast agent made in accordance with the present invention can be used not only as a drug-delivery agent for therapy but also as an MRI contrast agent for diagnosis. | 2021-01-14 |
20210008229 | TARGETED PHOTOACOUSTIC AGENTS AND USES THEREOF - The present application relates to photoacoustic agents, to kits comprising such photoacoustic agents and to uses thereof such as in methods for detecting a presence of a target in a subject. The photoacoustic agents comprise a photoacoustically active moiety (for example, a near infrared dye) that is coupled to a first bioorthogonal reactive group and optionally a targeting entity for a target that is coupled to a second bioorthogonal reactive group. | 2021-01-14 |
20210008230 | TARGETED MICROBUBBLE, PREPARATION METHOD THEREOF, AND USE THEREOF - The invention provides a targeted microbubble comprising a microbubble composed of a shell and a gas encapsulated in the shell, the shell is conjugated with a C4d antibody or a C3d antibody. The targeted microbubble of the present invention is employed as contrast agent for the ultrasonic imaging of C4d or C3d deposited in renal and cardiac allografts. The occurrence of antibody-mediated rejection (AMR) can be accurately diagnosed via qualitative and quantitative analysis. | 2021-01-14 |
20210008231 | IN VIVO IMAGING OF MATRIX METALLOPROTEINASES IN LUNG DISEASE - The present invention provides a method of imaging a subject's lung which comprises contacting the subject's lung with a matrix metalloproteinase inhibitor labeled with a radioisotope under conditions such that the inhibitor binds to matrix metalloproteinase in the lung, and then imaging the radiolabeled inhibitor bound to matrix metalloproteinase in the subject's lung. | 2021-01-14 |
20210008232 | CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER - A compound of Formula (I) or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt wherein the definitions of R | 2021-01-14 |
20210008233 | Controlled release of radionuclides - A brachytherapy device ( | 2021-01-14 |
20210008234 | ULTRAVIOLET STERILIZER - The ultraviolet sterilizer according to the present invention has: a flow channel pipe which has a treatment flow channel therein; a light source which emits ultraviolet rays; a condensing lens which condenses, toward the treatment flow channel, a portion of the ultraviolet rays emitted from the light source; and a reflector which reflects, toward the treatment flow channel, another portion of the ultraviolet rays emitted from the light source. | 2021-01-14 |
20210008235 | LIGHT DISINFECTION SYSTEM AND METHOD - A lighting system includes a light source configured to generate light to inactivate one or more pathogens. The light includes an inactivating portion having wavelengths in a range of 280 to 380 nanometers. | 2021-01-14 |
20210008236 | SYSTEM AND APPARATUS FOR SANITIZING A POINT OF CONTACT - An apparatus for sanitizing a point-of-contact surface may include a housing configured to be affixed about at least a portion of said point of contact. The housing may have an interior in or through which the point of contact may be accessed and an anterior opening for access to the interior. The apparatus may further include one or more sources of a sanitizing agent, such as germicidal light, configured to direct the sanitizing agent toward a location where at least a portion of the point-of-contact surface may be disposed. One or more of an anterior dome, an inner surface, and a posterior surface may also be configured to reflect the sanitizing agent toward the location where at least a portion of the point-of-contact surface may be disposed. | 2021-01-14 |
20210008237 | Disinfection Scrub For Male And Female Luer Connectors - A disinfection device is disclosed having a container, a scrub element, a disinfectant or antimicrobial agent, and a removable seal. The scrub element may be disposed on a base scrub. The container configured to define a chamber to contain the base scrub, scrub element, and disinfectant or antimicrobial agent. The base scrub and/or scrub element(s) are adapted to compress and contact the distal tip and sidewall of a male Luer connector, female Luer connector or hemodialysis connector upon insertion of the connector into the chamber. The removable seal prevents the disinfectant or the antimicrobial agent from exiting the chamber. Also described are methods of disinfecting a medical connector, and an assembly comprising a device for disinfecting a medical connector. | 2021-01-14 |
20210008238 | SANITIZING WIPE WITH METAL DETECTABLE PRINTED INDICIA - An article is provided having a substrate with an indicia printed on the substrate, where the indicia is printed with an ink that is detectable by in-line manufacturing production X-ray, metal, or magnetic detectors. A package for multiple such articles is also provided. A process for detecting a sanitizable substrate wipe with magnetic, metal, or X-ray detection equipment in a production setting is also provided. With process implementation article loss in a product can be detected thereby reducing precautionary product discard. | 2021-01-14 |
20210008239 | Medical Ozone Sterile Isotonic Saline Solution And Preparation Method And Application Thereof - A medical ozone sterile isotonic saline solution, a preparation method and an application thereof are provided. The medical ozone sterile isotonic saline solution is composed of medical ozone and a 0.9% sodium chloride injection. A ratio of a mass of the medical ozone to a volume of the 0.9% sodium chloride injection is equal to 3 μg/100 ml. The medical ozone is prepared into a medical injection (sterile isotonic saline solution) under normal temperature and normal pressure according to a specific ratio. The medical injection has stable properties, which is conductive to transportation and presents safety and effectiveness during use. The medical injection can be mass-produced, which is beneficial for clinical use and promotion. | 2021-01-14 |
20210008240 | METHOD FOR PRODUCING A STERILIZABLE STRAINER DISH HAVING A THREE-DIMENSIONALLY STRUCTURED BOTTOM - A method for producing a strainer dish for receiving medical objects to be disinfected or sterilized. A base surface is produced from a sheet metal blank in a first machining step. In a second machining step, the sheet metal blank or base surface is provided with holes to obtain a perforated starting shape. In a third machining step which takes place after the first and second machining steps, a perforated plane is produced, which can be divided into a flat inner section and an edge section. In a fourth machining step which takes place after the third machining step, a strainer dish shape is produced. The raw bottom corresponds to the flat inner section of the perforated plane. A fifth machining step, which takes place after the third machining step, at least partially produces a three-dimensionally structured bottom from the flat inner section. | 2021-01-14 |
20210008241 | WATER STERILIZATION MODULE AND AIR COOLER INCLUDING THE SAME - A water sterilization module includes a container including a water inlet and a water outlet and containing water therein, and a light source part mounted on a part of the container and irradiating sterilizing light into the container. The water inlet has a diameter larger than a diameter of the water outlet. | 2021-01-14 |
20210008242 | TUBULAR VOLATIZING DEVICE - A volatizer is provided including a multifunction cap secured over the open end of a body or other device, the chamber or other part of the device holding an amount of material to be extracted by selective volatization therein and including a thermo-indicator thereon or therein capable of deforming, actuating or otherwise indicating upon heating to a preselected temperature to provide an indication of the proper temperature for volatilization and extraction of the selected and or target compound from the material within the device. Also provided is a method of volatizing a substance. | 2021-01-14 |
20210008243 | PLASMA-BASED FILMS AND METHODS FOR MAKING AND USING THE SAME - The present invention relates to plasma-based films and in particular to flexible plasma-based films. The invention further relates to and to methods of making and using the flexible plasma-based films. Embodiments of the invention have been particularly developed for making flexible plasma-based films useful as a hemostat in the treatment and/or prevention of mild to severe as well as arterial bleedings, as an anti-adhesive sheet to reduce or prevent development of surgery-induced adhesions, as a wound healing patch, as a wound dressing, or as a film useful in hernia repair. Embodiments of the invention will be described hereinafter with reference to these applications. However, it will be appreciated that the invention is not limited to this particular field of use. | 2021-01-14 |
20210008244 | Adhesive Composition - The invention is directed to an adhesive complex coacervate composition, to a method of physically crosslinking an adhesive complex coacervate composition, to a method for adhering a tissue defect in a subject, and to the use of an adhesive complex coacervate composition. The adhesive complex coacervate composition of the invention comprises a polycation and a polyanion, wherein said polycation and polyanion together comprise on average at least two thermoresponsive moieties per polymer chain, said thermoresponsive moieties exhibiting a lower critical solution temperature, wherein said polycation comprises 5-70 mol % of thermoresponsive moieties and/or wherein said polyanion comprises 5-70 mol % of thermoresponsive moieties, and wherein said polycation and/or said polyanion is a graft or block copolymer comprising said thermoresponsive moieties. | 2021-01-14 |
20210008245 | IMPLANTABLE BODIES COMPRISING A REGIONAL COMPOSITE - The present patent application is directed to compositions and shaped structures implantable into mammalian bodies, the compositions and shaped structures having localized bioactive surfaces. | 2021-01-14 |
20210008246 | PHOTO-REACTIVE INKS AND THERMAL-CURABLE MATERIALS MADE THEREFROM - Provided herein photo-reactive inks, thermal-curable materials and objects (e.g., medical implants, scaffolds, devices, etc.) made therefrom, and methods of preparation and use thereof. | 2021-01-14 |
20210008247 | CURABLE CALCIUM PHOSPHATE COMPOSITIONS FOR USE WITH POROUS STRUCTURES AND METHODS OF USING THE SAME - Various embodiments disclosed relate to curable calcium phosphate compositions for use with porous structures and methods of using the same. In various embodiments, the present invention provides a curable calcium phosphate composition or a cured product thereof, with the curable calcium phosphate composition including calcium phosphate and a perfusion modifier. In various embodiments, the present invention provides an apparatus comprising a porous structure at least partially in contact with the curable calcium phosphate composition or a cured product thereof. The porous structure can include a porous substrate including a plurality of ligaments that define pores of the porous substrate, and a biocompatible metal coating on the plurality of ligaments of the porous substrate. | 2021-01-14 |
20210008248 | FIBRIN COMPOSITION, SUBSTRATE FOR REGENERATIVE MEDICINE, METHOD FOR MANUFACTURING FIBRIN COMPOSITION, AND KIT - An object of the present invention is to provide a fibrin composition manufactured by a method as a substitute for a method for manufacturing platelet-rich fibrin (PRF) triggered by the activation of a coagulation factor, a substrate for regenerative medicine using the fibrin composition, a method for manufacturing a fibrin composition, and a kit for being used in the method. According to the present invention, there is provided a fibrin composition including blocks, which each include a protein having repetitive Arg-Gly-Asp sequences derived from human collagen, fibrin, and platelets. | 2021-01-14 |
20210008249 | POROUS BIOMATERIALS FOR TISSUE REGENERATION - The present invention relates to a porous material having a scaffold comprising: one or more fibroin moieties A and one or more polysaccharide moieties B, wherein A and B are directly conjugated with another without an interconnecting linker structure. Moreover, the present invention refers to a method for preparing a porous material. The present invention further relates to an injectable composition comprising a particulate porous material according to the invention and to cosmetic and therapeutic uses thereof such as facial and body re-shaping as well as regenerating tissue. | 2021-01-14 |
20210008250 | ALLOGRAFT BONE PUTTY AND METHODS OF MAKING THE SAME - A method of preparing a reconstitutable implantable bone putty includes combining a bone matrix derived from human bone and gelatin particulates derived from human tissue at a concentration of the bone matrix by dry weight of 20 to 60 percent to form the reconstitutable implantable bone putty. Preparing the gelatin particulates includes supplying a gelatin precursor of bone or soft tissue from a human, treating the gelatin precursor with phosphoric acid to generate a gelatin-acid mixture, neutralizing the gelatin-acid mixture with an alkali to a pH between 6 and 8 to allow a gelatin-rich solution and a waste solution to separate, removing residual salts from the gelatin-rich solution to obtain purified gelatin, drying the purified gelatin, and reducing the purified gelatin to particulates having a largest dimension less than 300 μm. A method of preparing an implantable bone putty includes adding a reconstitution media to the reconstitutable implantable bone putty. | 2021-01-14 |
20210008251 | Fractionating Extracellular Matrix to Modulate Bioactivity and the Host Response - Provided herein are methods of fractionating extracellular matrix (ECM) materials, producing soluble and structural fractions having different immunological activities. Also provided are compositions and devices comprising the fractions. A method of immune modulation also is provided in which an amount of a soluble or structural ECM fraction prepared according to the methods provided herein is administered to a patient in an amount effective to modulate immune function, for example macrophage function. | 2021-01-14 |
20210008252 | THERMOPLASTIC MATERIALS INCORPORATING BIOACTIVE INORGANIC ADDITIVES - Composite materials comprising thermoplastic polymeric material such as polyaryletherketones (PAEKs) and inorganic additive species serving to increase the processing and resultant mechanical, thermal, and biological properties of said thermoplastic polymeric material which may be subsequently used in various medical applications after the two materials are mixed through thermal processing methods. The inorganic additive species may be a calcium salt, and may include fluorine ions. | 2021-01-14 |
20210008253 | ELONGATE SCAFFOLD COMPRISING INNER AND OUTER PORTION - The invention relates to an elongate scaffold comprising: an inner portion comprising a polymer; and an outer portion comprising a porous, nonwoven network of polymer fibers, wherein the packing density of the inner portion is greater than the packing density of the outer portion; wherein the inner portion (a) comprises a plurality of polymer fibers twisted around one another or (b) is a solid core comprising the polymer. The invention also relates to a scaffold precursor and a process for producing a scaffold, comprising twisting a scaffold precursor of the invention along its length. Further provided is a hybrid composition comprising the scaffold and cells and/or an active agent such as a drug, a nucleic acid, a nucleotide, a protein, a polypeptide, or an exosome. Therapeutic methods and uses of such hybrid compositions are also provided, for instance in tissue repair, wound healing, and in the treatment of a cardiac, bone, cartilage, tendon, ligament, liver, kidney joint, spleen, eye, spinal disc, connective tissue, or lung injury or disease or cancer, or an infection in a patient, and as tissue fillers for reconstructive or cosmetic applications. | 2021-01-14 |
20210008254 | ANTIBACTERIAL BIOMEDICAL IMPLANTS AND ASSOCIATED MATERIALS, APPARATUS, AND METHODS - Methods for improving the antibacterial characteristics of biomedical implants and related implants manufactured according to such methods. In some implementations, a biomedical implant comprising a silicon nitride ceramic material may be subjected to a surface roughening treatment so as to increase a surface roughness of at least a portion of the biomedical implant to a roughness profile having an arithmetic average of at least about 500 nm Ra. In some implementations, a coating may be applied to a biomedical implant. Such a coating may comprise a silicon nitride ceramic material, and may be applied instead of, or in addition to, the surface roughening treatment process. | 2021-01-14 |
20210008255 | DEVICE AND METHOD FOR WOUND THERAPY - A wound therapy device is disclosed. The wound therapy device may include a housing for covering at least a portion of a wound and for sealing to a body surface of a patient. The housing may also include a liquid collector for retaining liquid therein and a vacuum connection for coupling to a vacuum source. The vacuum connection may be in gaseous communication with the liquid collector. The vacuum connection may be separated from the liquid collector by a liquid barrier. | 2021-01-14 |
20210008256 | GRASPABLE SURGICAL DEVICE - A system for adapting a tubular surgical device for grasping by a surgical instrument is provided that has a distal portion, an adaptor positioned proximally and configured to be disposed about or within a lumen of the tubular surgical device, which has an effective durometer to resist crushing by the surgical instrument. In some embodiments, the adaptor is configured with an external diameter greater than the internal diameter of the lumen of the tubular surgical device. In some embodiments, the adaptor is configured with an external diameter less than or equal to the internal diameter of the tubular surgical device. | 2021-01-14 |
20210008257 | SURGICAL SUCTION SYSTEM - A surgical suction system. The surgical suction system includes a large bore Yankauer suction device having a distal tip with a first diameter, and a proximal end with exterior hose barbs and a second diameter. The second diameter is greater than the first diameter such that a channel extending through the large bore Yankauer suction device may have an increasing diameter from the distal tip to the proximal end. The surgical system also includes cannulated tubing having a distal end and a proximal end, the distal end configured to mate with the exterior hose barbs of the Yankauer suction device. The surgical system further includes an adapter having a distal end with exterior hose barbs and a proximal end. The exterior hose barbs configured to mate with the proximal end of the cannulated tubing. The proximal end of the adapter is configured to connect to a port to a canister, wall vacuum, or other biological material collection device. | 2021-01-14 |
20210008258 | WOUND DRESSING APPARATUS - The wound dressing apparatus facilitates administration of combined negative pressure and positive pressure treatment at a wound site. The wound dressing apparatus includes a wound dome having a substantially hollow dome interior, a manifold that is in fluid communication with the dome interior, a first passage adapted to connect to a negative pressure source to the dome interior, and a second passage adapted to connect to a positive pressure source to the manifold. | 2021-01-14 |
20210008259 | SYSTEMS AND METHODS FOR CONTROLLING NEGATIVE PRESSURE THERAPY WITH FLUID INSTILLATION THERAPY AND CLEANSING - Systems, apparatuses, and methods for providing negative pressure and/or instillation fluids to a tissue site are disclosed. Some embodiments are illustrative of an apparatus or system for delivering negative-pressure and/or therapeutic solution of fluids to a tissue site, which can be used in conjunction with sensing properties of fluids extracted from a tissue site and/or instilled at a tissue site. For example, an apparatus may comprise a dressing interface or connector that includes a pH sensor, a humidity sensor, a temperature sensor and/or a pressure sensor embodied on a single pad within the connector and proximate the tissue site to provide data indicative of acidity, humidity, temperature and pressure. Such apparatus may further comprise algorithms for processing such data for detecting leakage and blockage as well as providing information relating to the progression of healing of wounds at the tissue site. An illustrative method may comprise positioning a dressing interface having a pH sensor, a temperature sensor, a humidity sensor, and a pressure sensor at a tissue site, and applying reduced pressure to the dressing interface to draw fluids from the tissue interface in contact with the sensors to sense the pH, temperature, humidity, and pressure properties of the fluids flowing from the tissue site. The method may further comprise providing fluid data indicative of such properties to a control device for processing the fluid data and transmitting the data to another component in the system. | 2021-01-14 |
20210008260 | Spiral Flow-Inducing Exo-Graft - A spiral flow-inducing exo-graft is a non-blood contacting helically shaped device that wraps around the outside of a blood-carrying conduit and manipulates hemodynamic flow-patterns. The blood-carrying conduit can be a natural tissue blood vessel or an artificial graft. | 2021-01-14 |
20210008261 | INTRAVASCULAR BLOOD PUMPS AND METHODS OF MANUFACTURE AND USE - Catheter blood pump that include an expandable pump portion extending distally from an elongate shaft. The pump portions include an expandable impeller housing including an expandable blood conduit that defines a blood lumen between an inflow and an outflow. The pump portions include one or more expandable impellers disposed at least partially within the blood lumen. | 2021-01-14 |
20210008262 | Rotary Seal for Cantilevered Rotor Pump and Methods for Axial Flow Blood Pumping - Blood pump devices having improved rotary seals for sealing a bearing assembly supporting a rotor provided herein. Such rotary seals are particularly suited for use in blood pump devices that include rotors having cantilevered supported through a sealed mechanical bearing disposed outside a blood flow path of the device to avoid thrombus formation caused by blood contact with the bearing. The rotary seal can include a first and second face seal that are preloaded with a deflectable compliance member incorporated into the pump housing or a pair of magnets. Such rotary seals can instead or further utilize tight fitment between components or a bio-absorbable fill material to seal an interface between the rotor shaft and pump housing to seal the bearing assembly from fluid flowing through the pump. | 2021-01-14 |
20210008263 | CIRCULATORY ASSIST PUMP - A minimally invasive circulatory support platform that utilizes an aortic stent pump or pumps. The platform uses a low profile catheter-based techniques and provides temporary and chronic circulatory support depending on the needs of the patient. Also described is a catheter-based temporary assist pump to treat patients with acute decompensated heart failure and provide circulatory support to subjects undergoing high risk percutaneous coronary intervention (“PCI”). Further described is a wirelessly powered circulatory assist pump for providing chronic circulatory support for heart failure patients. The platform and system are relatively easy to place, have higher flow rates than existing systems, and provide improvements in the patient's renal function. | 2021-01-14 |
20210008264 | CIRCULATORY SUPPORT DEVIC - A circulatory support device includes a flexible cannula having a fluid outlet at a proximal end; and a pump assembly disposed at a distal end of the flexible cannula. The pump assembly includes a pump housing having a fluid inlet defined therein; a motor disposed within a distal end of the housing; and an impeller, driven to rotate by the motor, and configured to push blood toward the fluid outlet. | 2021-01-14 |
20210008265 | ADAPTIVE SYSTEM FOR BLOOD FLUID REMOVAL - Methods for monitoring patient parameters and blood fluid removal system parameters include identifying those system parameters that result in improved patient parameters or in worsened patient parameters. By comparing the patient's past responses to system parameters or changes in system parameters, a blood fluid removal system may be able to avoid future use of parameters that may harm the patient and may be able to learn which parameters are likely to be most effective in treating the patient in a blood fluid removal session. | 2021-01-14 |
20210008266 | PROCESS FOR REMOVING COBALT, LEAD, CADMIUM AND CHROMIUM IONS FROM BODILY FLUIDS USING METALLATE ION EXCHANGE COMPOSITIONS - A process for removing Co | 2021-01-14 |
20210008267 | PROCESS FOR REMOVING STRONTIUM IONS FROM BODILY FLUIDS USING METALLATE ION EXCHANGE COMPOSITIONS - A process for removing Sr | 2021-01-14 |
20210008268 | SYSTEMS AND METHODS FOR PERFORMING MEDICAL PROCEDURES INVOLVING ACCESSING THE LYMPHATIC SYSTEM - System and methods are provided for harvesting one or more organs, e.g., a lung from a donor body. In one embodiment, a distal end of a tubular member is introduced into the donor body's vasculature via a percutaneous access site, and the tubular member is manipulated until the distal end of the tubular member is disposed within the thoracic duct. Fluid is removed from the thoracic duct through the tubular member to a location exterior to the patient's body, and one or more organs are removed from the donor body. Optionally, one or more parameters within the thoracic duct or other parameters of the donor body may be monitored and fluid removal may be adjusted to reduce fluid accumulation within the one or more organs. | 2021-01-14 |